Supplementary Online Content
|
|
- Buddy Pitts
- 5 years ago
- Views:
Transcription
1 Supplementary Online Content Raebel MA, Newcomer SR, Reifler LM, et al. Chronic use of opioid medications before and after bariatric surgery. JAMA. doi: /jama efigure. Opioid Dispensings in 60 Days Before and 60 Days After Bariatric Surgery etable 1. Opioid Classification and Morphine Equivalents Conversion Factors for Opioids Administered by Tablet, Capsule, Liquid, Transdermal Patch, and Transmucosal Formulations etable 2. ICD-9 Codes for Comorbid Diagnosis of Substance Abuse, Anxiety, Posttraumatic Stress Disorder, and/or Depression etable 3. ICD-9 Codes for Inclusion and Exclusion of Chronic Pain Diagnoses etable 4. Therapeutic Classes, Generic Names, and Selected Brand Names of Covariate Medications etable 5. Types of Opioids Dispensed During the Year Before and the Year After Bariatric Surgery Among Presurgery Chronic Opioid Users etable 6. Types of Opioids Used Before and After Bariatric Surgery Among 933 Individuals With Chronic Opioid Use Before Bariatric Surgery etable 7. Unadjusted Characteristics of Chronic Opioid Users According to Whether or Not Both Presurgery and Postsurgery Body Mass Indexes (BMIs) Data Were Available etable 8. Presurgery and Postsurgery Use of Opioids and Selected Other Analgesic and Adjunctive Pain Medication Classes Among Presurgery Chronic Opioid Users With Presurgery Chronic Pain Diagnoses This supplementary material has been provided by the authors to give readers additional information about their work.
2 efigure. Opioid Dispensings in 60 Days Before and 60 Days After Bariatric Surgery
3 3 etable 1. Opioid Classification and Morphine Equivalents Conversion Factors for Opioids Administered by Tablet, Capsule, Liquid, Transdermal Patch, and Transmucosal Formulations a Opioid Conversion Factor per mg Opioid Comments Short-acting, Schedule II Codeine sulfate 0.15 Hydromorphone 4 Meperidine hydrochloride 0.1 Morphine sulfate 1 Oxycodone (with or without 1.5 acetaminophen, ibuprofen, aspirin) Oxymorphone 3 Fentanyl citrate, transmucosal (lollipop, lozenges) Assumes 50% bioavailability Long-acting, Schedule II Morphine sulfate, sustained release 1 Fentanyl, transdermal 2.4 Assumes one patch delivers the dispensed micrograms/hour over each 24-hour day for three days Methadone 3 Oxycodone hydrochloride, controlled 1.5 release Oxymorphone, sustained release 3 Levorphanol tartrate 11 Non-Schedule II Butalbital and codeine (with or without aspirin, ibuprofen, acetaminophen) 0.15 Codeine+(acetaminophen, ibuprofen, aspirin, or carisoprodol) 0.15 Dihydrocodeine (with or without aspirin, ibuprofen, acetaminophen) 0.25 Hydrocodone+(acetaminophen, ibuprofen, aspirin, or homatropine) 1 Pentazocine (with or without aspirin, ibuprofen, acetaminophen) 0.37 Propoxyphene (with or without acetaminophen, ibuprofen, aspirin) 0.23 Tapentadol 2.5 Tramadol with or without aspirin 0.1 No dihydrocodeine products were dispensed in this study No tapentadol products were dispensed in this study a Adapted from Von Korff M, Saunders K, Ray GT, et al. De facto long-term opioid therapy for noncancer pain. Clin J Pain. 2008;24:521 7.
4 4 etable 2. ICD9 Codes for Comorbid Diagnosis of Substance Abuse, Anxiety, Post- Traumatic Stress Disorder, and/or Depression a ICD9 Code Category Description 291.x Substance abuse Alcohol induced mental disorders 292.x Substance abuse Drug induced mental disorders 303.x Substance abuse Alcohol dependence syndrome 304.x Substance abuse Drug dependence 305.x Substance abuse Nondependent abuse of drugs 300.x Anxiety Anxiety, dissociative, and somatoform disorders PTSD Posttraumatic stress disorder Depression Major depressive disorder, single episode Depression Major depressive disorder, multiple episodes Depression Dysthymic disorder Depression Adjustment disorder with depressed mood Depression Prolonged depressive reaction Depression Adjustment disorder with mixed anxiety and depressed mood 311.x Depression Depressive disorder, not elsewhere classified Bipolar Bipolar I disorder, single manic episode Bipolar Bipolar I disorder, most recent episode (or current) manic Bipolar Bipolar I disorder, most recent episode (or current) depressed Bipolar Bipolar I disorder, most recent episode (or current) mixed Bipolar Bipolar I disorder, most recent episode (or current) unspecified 296.8x Bipolar Other and unspecified bipolar disorders a Cohort members were considered to have any of these conditions if they had at least one recorded diagnosis code in any setting in the year prior to bariatric surgery.
5 5 etable 3. ICD9 codes for Inclusion and Exclusion of Chronic Pain Diagnoses ICD9 Codes for Inclusion of Chronic Pain Diagnoses a, b ICD9 Code 550.x, 551.x, 552.x, 553.x, 789.0x 274, 274.0, , , , , 714, 714.0x, 714.1x, 714.2x, 714.3x, 714.4x, 714.5x, 714.6x, 714.7x, 714.8, , 714.9x, 715.x, 716.x, 719.3, Abdominal pain/hernia Arthritis 720.x, 721.2, 721.3, , , 721.5, 721.6, Back pain 721.7, 721.8, 721.9, , , 722.1, , , 722.2, , , , , 722.5, , , 722.6, 722.7, , , , , 722.8, , , , 722.9, , , , 724, 724.0, , , , , 724.1, 724.2, 724.3, 724.4, 724.5, 724.6, 724.7, , , , 724.8, 724.9, 737.x, 738.4, 738.5, 739.2, 739.3, 739.4, 756.1, , , 805, 805.2, 805.4, 805.6, 805.8, 839.2, , , , 846, 846.0, 846.1, 846.2, 846.3, 846.8, 846.9, 847.1, 847.2, 847.3, 847.4, 847.9, , 354.0, Carpal tunnel Category 733.6, , 848.3, Costochronditis and intracostal muscle injury 729, Fibromylagia 800.x, 801.x, 802.x, 803.x, 804.x, 805.x, 806.x, 807.x, Fractures and contusions 808.x, 809.x, 810.x, 811.x, 812.x, 813.x, 814.x, 815.x, 816.x, 817.x, 818.x, 819.x, 820.x, 821.x, 822.x, 823.x, 824.x, 825.x, 826.x, 827.x, 828.x, 829.x, 920.x, 921.x, 922.x, 923.x, 924.x , 338, 338.2, , , , , General chronic pain 338.4, 739.9, 780.9, x, 592.x Kidney/gall stones 354.4, 713.5, , , , , 723.4, Limb extremity pain , 724.3, , 726.5, , , , 726.9, , , 727, 727.0x, 727.1x, 727.2x, 727.3x, 727.4x, 727.5x, 727.6, , , , , , , , , , 727.7x, 727.8x, 727.9x, , 729.2, 729.5, 739.6, 739.7, , 755.9, , , 840.9, 842.1, , 843.8, 843.9, 844.8, 844.9, 845, , 845.1, , 625.0x, 625.1x, 625.2x, 625.3x, 625.4x, 625.5x, Menstrual pain 625.7x, 625.8x, 625.9x 346.x Migraines 721, 721.0, 721.1, 722, 722.0, 722.4, , , Neck pain 723.x, , 739.1, 805.0, , , , , , , , , , 847, x, 354.x, 355.x, 356.x, 357.x, Neuropathy 715.x Osteoarthritis
6 6 ICD9 Code 306, , 710.5, 725, , 729.4, 733.6, 739.8, , , 848.3, , x, 717.2, 717.3, 717.5, 717.7, , 717.9, 718.1, , , , , 719, , 719.4, , , , , , , , , , , 726, 726.0, 726.1, , , , 726.2, , , , , , 726.4, 726.6, , , , , , , 726.7, , , 726.8, , 831, 835, 836, 836.1, 836.3, , 839.8, 840, 840.3, 840.4, 840.5, 840.6, 840.7, 840.8, 841.9, 842, , , 844.1, , 339.1, , , , 784, 784.0, x, 526.9x, 784.9x, 830.0x, 830.1x Category Other CMP Pain in joint Tension headache TMD/TMJ ICD9 Malignant Cancer, Dementia, and Psychosis Codes that Precluded Classification of Chronic Pain Diagnoses c d Malignant cancer 290.0x, 290.1, x 290.9x 291.2x 294.1, , x 297.x 298.x 299.x x, 315.1x, 315.2x, 315.3x, 315.5x 317.x, 318.x, 319.x 331.x Dementia and psychosis a The goal of including this list of diagnoses in the definition of chronic pain diagnoses is to maximize the sensitivity of identifying individuals with chronic pain prior to bariatric surgery. Based on work from Von Korff et al, 20 Boudreau et al, 5 and Campbell et al, 41 these diagnoses were all identified as being associated with long term use of opioids at Group Health and KP Northern California over the ten-year period from Inclusion Criteria: Overall, two groups of diagnoses were included: (1) Non-specific chronic pain (NCP): General chronic pain and migraines, tension headache, abdominal pain, hernia, kidney/gall stones, menstrual pain, neuropathy, temporomandibular pain (2) Chronic musculoskeletal pain (CMP): back pain, neck pain, fibromyalgia, arthritis, carpal tunnel, limb-extremity pain, pain in joint, "other" CMP, osteoarthritis, fractures and contusions, costochrondritis and intracostal muscle injury To meet the definition of having diagnosed chronic pain pre-bariatric surgery, the individual must have at least two clinic, , or phone encounters with CMP and/or NCP diagnoses from the list below. There must be at least 90 days elapsed between the first such encounter and the last such encounter in the year prior to surgery. b Any of these diagnoses associated with physical therapy or rehabilitation departments/providers were not included. c Individuals were not classified as having diagnosed chronic pain if they had a diagnosis of malignant cancer or dementia or psychosis in the year prior to bariatric surgery d Except for non-melanoma skin cancer (ICD9 code 173)
7 7 etable 4. Therapeutic Classes, Generic Names, and Selected Brand Names of Covariate Medications Antidepressants AMITRIP HCL/CHLORDIAZEPOXIDE AMITRIPTYLINE, AMITRIPTYLINE HCL AMOXAPINE BUPROPION, BUPROPION HCL, BUPROPION HYDROBROMIDE, WELLBUTRIN SR CITALOPRAM, CITALOPRAM HBR CLOMIPRAMINE, CLOMIPRAMINE HCL DESIPRAMINE, DESIPRAMINE HCL DESVENLAFAXINE SUCCINATE DOXEPIN, DOXEPIN HCL DULOXETINE, DULOXETINE HCL, CYMBALTA ESCITALOPRAM, ESCITALOPRAM OXALATE FLUOXETINE, FLUOXETINE HCL FLUVOXAMINE, FLUVOXAMINE MALEATE IMIPRAMINE, IMIPRAMINE HCL MAPROTILINE MILNACIPRAN, MILNACIPRAN HCL MIRTAZAPINE NEFAZODONE, NEFAZODONE HCL NORTRIPTYLINE, NORTRIPTYLINE HCL OLANZAPINE/FLUOXETINE HCL PAROXETINE, PAROXETINE HCL PERPHENAZINE/AMITRIPTYLINE HCL PHENELZINE SULFATE PROTRIPTYLINE, PROTRIPTYLINE HCL SELEGILINE SERTRALINE, SERTRALINE HCL, ZOLOFT TRANYLCYPROMINE, TRANYLCYPROMINE SULFATE TRAZODONE, TRAZODONE HCL TRIMIPRAMINE MALEATE VENLAFAXINE, VENLAFAXINE HCL, EFFEXOR XR Antiepileptics ATROPINE/HYOSCYAMINE/PHENOBARBITAL/SCOPOLAMINE BELLADONNA ALKALOIDS/PHENOBARBITAL CARBAMAZEPINE, CARBAMAZEPINE COMPOUND CLONAZEPAM, CLONAZEPAM ORAL SUSPENSION CLONIDINE-GABAPENTIN-KETAMINE DIVALPROEX SODIUM, VALPROATE, VALPROATE SODIUM, VALPROIC ACID
8 8 Antiepileptics (continued) ERGOTAMINE/BELLADONNA/PHENOBARB ETHOSUXIMIDE FELBAMATE GABAPENTIN GABAPENTIN-KETOPROFEN-LIDOCAINE LACOSAMIDE LAMOTRIGINE LEVETIRACETAM OXCARBAZEPINE PHENAZOPYRIDINE-BUTABARBITAL-HYOSCYAMINE PHENOBARB/HYOSC SUL/ATROP SULF/SCOP PHENOBARB/HYOSCY/ATROPINE/SCOP PHENOBARBITAL, PHENOBARBITAL COMPOUND PHENYTOIN, PHENYTOIN SODIUM EXTENDED PREGABALIN PRIMIDONE TIAGABINE HCL TOPIRAMATE ZONISAMIDE Anxiolytics and Sedative Hypnotics ACETAMINOPHEN/DICHLORALPHENAZONE/ISOMETHEPTENE ALPRAZOLAM AMITRIP HCL/CHLORDIAZEPOXIDE ATROPINE/HYOSCYAMINE/PHENOBARBITAL/SCOPOLAMINE BELLADONNA ALKALOIDS/PHENOBARBITAL BUSPIRONE, BUSPIRONE HCL CHLORAL HYDRATE CHLORDIAZEPOXIDE, CHLORDIAZEPOXIDE HCL CHLORDIAZEPOXIDE/CLIDINIUM, CHLORDIAZEPOXIDE/CLIDINIUM BR, CLIDINIUM & CHLORDIAZEPOXIDE CLORAZEPATE, CLORAZEPATE DIPOTASSIUM DEXMEDETOMIDINE-STUDY DRUG DIAZEPAM ERGOTAMINE/BELLADONNA/PHENOBARB ESTAZOLAM ESZOPICLONE FLURAZEPAM, FLURAZEPAM HCL HYDROXYZINE, HYDROXYZINE HCL, HYDROXYZINE PAMOATE LORAZEPAM LORTAB/ADVIL/PROZAC/CHERRY SYR PAINCT
9 9 Anxiolytics and Sedative Hypnotics (continued) MEPROBAMATE MIDAZOLAM OXAZEPAM PHENAZOPYRIDINE-BUTABARBITAL-HYOSCYAMINE PHENOBARB/HYOSC SUL/ATROP SULF/SCOP, PHENOBARB/HYOSCY/ATROPINE/SCOP PHENOBARBITAL, PHENOBARBITAL COMPOUND RAMELTEON SECOBARBITAL TEMAZEPAM TRIAZOLAM ZALEPLON ZOLPIDEM, ZOLPIDEM TARTRATE Corticosteroids, oral BETAMETHASONE BUDESONIDE DEXAMETHASONE HYDROCORTISONE METHYLPREDNISOLONE PREDNISOLONE, PREDNISOLONE SOD PHOSPHATE PREDNISONE Muscle relaxants CARISOPRODOL CARISOPRODOL/ASPIRIN CHLORZOXAZONE CODEINE PHOS/CARISOPRODOL/ASA CYCLOBENZAPRINE, CYCLOBENZAPRINE HCL METAXALONE METHOCARBAMOL ORPHENADRINE, ORPHENADRINE CITRATE ORPHENADRINE W/ ASPIRIN & CAFF, ORPHENADRINE/ASPIRIN/CAFFEINE TIZANIDINE, TIZANIDINE HCL Non-narcotic analgesics ACETAMINOPHEN ACETAMINOPHEN-ISOMETHEPTE ACETAMINOPHEN-ISOMETHEPTENE-CAFFEINE ACETAMINOPHEN-ISOMETHEPTENE-DICHLORALPHENAZONE, ACETAMINOPHEN/ISOMETHEPTENE/DICHLPH, ACETAMINOPHEN/DICHLORALPHENAZONE/ISOMETHEPTENE ACETAMINOPHEN/BUTALBITAL
10 10 Non-narcotic analgesics (continued) ACETAMINOPHEN/BUTALBITAL/CAFFEINE ASPIRIN, ASPIRIN EC ASPIRIN-ACETAMINOPHEN-CAFFEINE ASPIRIN/BUTALBITAL/CAFFEINE, BUTALBITAL/ASPIRIN/CAFFEINE ATROPINE/BENZOATE/HYOSCYAMINE/METHENAMINE/METHYLENE BLUE/PHENYL SALICYLATE BUTALBITAL-ACETAMINOPHEN, BUTALBITAL/ACETAMINOPHEN BUTALBITAL-ACETAMINOPHEN-CAFFEINE CARISOPRODOL/ASPIRIN CELECOXIB CHOLINE SALICYLATE/MAGNESIUM SALICYLATE DICLOFENAC EPOLAMINE, DICLOFENAC POTASSIUM, DICLOFENAC SODIUM DICLOFENAC SODIUM/MISOPROSTOL, DICLOFENAC W/ MISOPROSTOL DIFLUNISAL ETODOLAC FLURBIPROFEN, FLURBIPROFEN SODIUM GABAPENTIN-KETOPROFEN-LIDOCAINE HYDROQUINONE,SALICY ACID IN TRIAMCIN OIN HYOSCYAMINE/METHENAMINE/METHYLENE BLUE/PHENYL SALICYLATE/SODIUM PHOSPHATE, MONOBASIC IBUPROFEN IBUPROFEN/PSEUDOEPHEDRINE INDOMETHACIN, INDOMETHACIN COMPOUND KETOPROFEN KETOROLAC TROMETHAMINE LANSOPRAZOLE-NAPROXEN MECLOFENAMATE SODIUM MEFENAMIC ACID MELOXICAM NABUMETONE NAPROXEN, NAPROXEN SODIUM ORPHENADRINE/ASPIRIN/CAFFEINE OXAPROZIN PIROXICAM SALSALATE SULINDAC SUMATRIPTAN SUCC/NAPROXEN SOD TOLMETIN SODIUM TROLAMINE SALICYLATE TROLAMINE SALICYLATE/ALOE VERA
11 11 etable 5. Types of Opioids Dispensed during the Year before and the Year after Bariatric Surgery among Pre-surgery Chronic Opioid Users Type a Before Surgery % of Dispensings After Surgery % of Dispensings Direction of Change Morphine Equivalents Conversion Factor Hydrocodone combinations Decrease 1 Oxycodone Increase 1.5 Morphine sulfate - LA Increase 1 Propoxyphene Decrease 0.23 Tramadol Decrease 0.1 Codeine combinations Decrease 0.15 Oxycodone CR Increase 1.5 Fentanyl transdermal Increase 2.4 Methadone Increase 3 Hydromorphone Increase 4 Morphine sulfate Increase 1 Oxymorphone-LA Decrease 3 Tramadol-LA Decrease 0.1 Butalbital & codeine Increase 0.15 Codeine sulfate < 0.1 < 0.1 Decrease 0.15 Pentazocine < 0.1 < 0.1 Decrease 0.37 Meperidine < 0.1 < 0.1 Increase 0.1 Levorphanol tartrate < 0.1 None Decrease 11 Oxymorphone None < 0.1 Increase 3 a Transmucosal fentanyl was not dispensed
12 12 etable 6. Types of Opioid Used before and after Bariatric Surgery among 933 Individuals with Chronic Opioid Use before Bariatric Surgery Time Period Relative to Type of Opioid Bariatric Surgery a Non-Schedule II b Short-acting Schedule II c Long-acting Schedule II d % of Patients with Use e % of total Morphine Equivalents (95% CI) % with Use % of total Morphine Equivalents (95% CI) % with Use % of total Morphine Equivalents (95% CI) One Year Before ( ) ( ) ( ) First Year After ( ) ( ) ( ) Second Year After ( ) ( ) ( ) a One year before is defined as days -335 through -1 prior to surgery; first year after is defined as days 30 through 364 after surgery, and second year after is defined as days 365 through 729 after surgery b Non-Schedule II = propoxyphene (with or without acetaminophen, ibuprofen, aspirin), codeine plus acetaminophen, ibuprofen, aspirin, or carisoprodol; butalbital and codeine (with or without aspirin, ibuprofen, acetaminophen); hydrocodone (with or without acetaminophen, ibuprofen, aspirin or homatropine); tramadol (with or without aspirin); and pentazocine (with or without aspirin, ibuprofen, or acetaminophen). c Short acting Schedule II = morphine sulfate; codeine sulfate; hydromorphone; meperidine; fentanyl transmucosal; oxymorphone; oxycodone. d Long acting Schedule II = morphine sulfate sustained release (SR); fentanyl, transdermal; levorphanol; oxycodone controlled release (CR); methadone; oxymorphone sustained release. e Percentage of Individuals with Use: percent of chronic opioid users possessing the opioid of interest (i.e., non-schedule II, SA Schedule II or LA Schedule II) for at least one day during the time period of interest (i.e., one year before, first year after, second year after). Proportions across the three opioid types sum greater than 100% because individuals could possess more than one type of opioid during the same time period of interest.
13 etable 7. Unadjusted Characteristics of Chronic Opioid Users according to whether or not both Pre- and Post- Surgery Body Mass Index (BMI) Data were Available Characteristic Sociodemographics All Individuals (n = 933) BMI Data Available (n = 647) BMI Data Not Available (n = 286) Age at surgery, median (5th, 95th percentile) 51 (33, 65) 51 (33, 65) 50 (32, 65) 0.07 Gender, % Female 737 (79) 512 (79) 225 (79) 0.87 Race and Ethnicity (%) <0.001 Black 60 (6) 44 (7) 16 (6) White 660 (71) 493 (76) 167 (58) Hispanic, any race 78 (8) 55 (9) 23 (8) Other race 25 (3) 23 (4) 2 (1) Not available 110 (12) 32 (5) 78 (27) Tobacco Use <0.001 Ever Use 339 (36) 300 (46) 39 (14) Never Use 261 (28) 255 (39) 6 (2) Not Available 333 (36) 92 (14) 241 (84) % with less than high school education, median (5th, 95th percentile) b 14 (3, 41) 15 (3, 41) 13 (3, 36) Insurance (%) 0.10 Medicare 81 (9) 66 (10) 15 (5) Medicaid 7 (<1) 5 (<1) 2 (<1) Commercial 723 (78) 487 (75) 236 (83) Multiple or other types 108 (12) 79 (12) 29 (10) Not available 14 (2) 10 (2) 4 (1) Clinical Characteristics Number of comorbidities pre-surgery year, median (5th, 95th percentile) c 4 (1, 8) 4 (1, 8) 4 (2, 9) Selected diagnoses pre-surgery year (%) Chronic pain d 666 (71) 477 (74) 189 (66) P-Value a
14 Characteristic All Individuals (n = 933) BMI Data Available (n = 647) BMI Data Not Available (n = 286) Substance abuse e 159 (17) 95 (15) 64 (22) Anxiety e 217 (23) 136 (21) 81 (28) PTSD e 22 (2) 4 (1) 18 (3) 0.20 Depression e 301 (32) 188 (29) 113 (40) Bipolar disorder e 35 (4) 28 (4) 7 (2) 0.16 Outpatient visits pre-surgery year, median (5th, 95th percentile) 16 (5, 48) 16 (5, 48) 19 (5, 47) 0.01 Type of Surgery 0.09 Gastric sleeve 30 (3) 19 (3) 11 (4) Laparoscopic (Lap) Band 114 (12) 84 (13) 30 (11) Lap Roux-en-Y gastric bypass (RYGB) 564 (61) 402 (62) 162 (57) Open RYGB 148 (16) 96 (15) 52 (18) Other or more than one type 77 (8) 46 (7) 31 (11) First bariatric surgery re-intervention after initial bariatric procedure (%) f 168 (18) 107 (17) 61 (21) 0.08 First inpatient surgery (not bariatric) after initial bariatric procedure (%) f 68 (7) 43 (7) 25 (9) 0.26 Incident chronic pain diagnosis the post-surgery year (%) d 111 (12) 73 (11) 38 (13) 0.38 a Chi-square tests for categorical variables and Kruskal-Wallis tests for continuous variables b % of community members > 25 years of age with <= 12 years education; measured from Census 2000 data c Quan comorbidity index; lower scores represent lower comorbidity burden d At least two coded diagnoses at least 90 days apart e At least one coded diagnosis during the year prior to surgery f 15 to 364 days after initial bariatric procedure P-Value a
15 15 etable 8. Pre- and Post-surgery Use of Opioids and Selected Other Analgesic and Adjunctive Pain Medication Classes among Pre-surgery Chronic Opioid Users with Pre-surgery Chronic Pain Diagnoses Opioid Use Total Morphine Equivalents Dispensed mean (SD) Fibromyalgia a (n = 104) 17,590 (24,310) 21,228 (29,900) Back pain b (n = 193) 16,211 (24,648) 18,358 (25,785) Osteoarthritis c (n = 119) 16,719 (36,205) 19,069 (46,446) Back pain and osteoarthritis d (n = 151) 15,658 (25,841) 17,450 (31,093) Other chronic pain types e (n = 99) 12,927 (18,600) Presurgery Postsurgery Presurgery Postsurgery Presurgery Postsurgery Presurgery Postsurgery Presurgery Postsurgery 15,200 (21,655) median (25 th, 75 th percentile) 7665 (3613, 17,342) 9667 (3103, 24,048) 8652 (4265, 17,417) 9510 (3720, 20,663) 6000 (2975, 13,635) 6550 (3000, 15,010) 7812 (4275, 13,350) 6735 (3025, 17,037) 6435 (3540, 14,284) 8135 (3150, 17,880) Use of selected other analgesic and adjunctive pain medication classes, n (%) Antidepressant 83 (80) 83 (80) 142 (74) 134 (69) 69 (58) 61 (51) f 100 (66) 91 (60) f 58 (59) 58 (59) Antiepileptic 36 (35) 36 (35) 59 (31) 61 (32) 22 (19) 17 (14) 45 (30) 38 (25) 26 (26) 24 (24) Antianxiety 43 (41) 52 (50) f 87 (45) 86 (45) 39 (33) 41 (35) 42 (28) 52 (34) 34 (34) 40 (40) Oral corticosteroid 13 (13) 10 (10) 25 (13) 14 (7) f 12 (10) 11 (9) 17 (11) 19 (13) 7 (7) 7 (7) Muscle relaxant 52 (50) 42 (40) f 91 (47) 67 (35) g 22 (19) 18 (15) 55 (36) 36 (24) g 20 (20) 22 (22) Non-narcotic analgesic 95 (91) 85 (82) g 174 (90) 167 (87) 109 (92) 105 (88) 149 (99) 136 (90) h 91 (92) 91 (92) a With or without a pre-surgery diagnosis of osteoarthritis or back pain; n = 76 (73%) also had at least one pre-surgery non-specific chronic pain diagnosis b No pre-surgery osteoarthritis or fibromyalgia diagnosis; n = 127 (66%) also had at least one pre-surgery non-specific chronic pain diagnosis c No pre-surgery back pain or fibromyalgia diagnosis; 61 (51%) also had at least one pre-surgery non-specific chronic pain diagnosis d No pre-surgery fibromyalgia diagnosis; 96 (64%) also had at least one pre-surgery non-specific chronic pain diagnosis e No pre-surgery back pain, osteoarthritis, or fibromyalgia diagnosis; 74 (75%) also had at least one pre-surgery non-specific chronic pain diagnosis f 0.01 < p < 0.05 pre- to post-surgery pair difference; McNemar s test g < p < 0.01 pre- to post-surgery pair difference; McNemar s test h p < pre- to post-surgery pair difference; McNemar s test
Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT
Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup Opioid Prescribing Metrics - DRAFT Definitions: Days Supply: The total of all opioid prescriptions dispensed during the calendar quarter
More informationForensic Toxicology Scope of Testing and Detection Limits
Forensic Toxicology Scope of Testing and Detection Limits Table of Contents QUALITATIVE ANALYSES... 2 Volatile Screen by GC/FID... 2 Carbon Monoxide by Microdiffusion... 2 Ethylene Glycol by GC/MS... 2
More informationMedicines Formulary BNF Section 4 Central Nervous System
Medicines BNF Section 4 4.1 Hypnotics and anxiolytics Chloral Hydrate 500mg/5ml Solution Clomethiazole 192mg Capsules Lormetazepam Tablets Melatonin Capsules Nitrazepam Suspension Nitrazepam Tablets Temazepam
More informationINTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE, MARYLAND QUARTERLY REPORT: FOURTH QUARTER, 2008 AND 2008 SUMMARY
INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE, MARYLAND QUARTERLY REPORT: FOURTH QUARTER, 2008 AND 2008 SUMMARY A report from the Office of Epidemiology and Planning Baltimore
More informationINTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE CITY
2009 FINAL REPORT INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE CITY This report was prepared by: Dr. Jose Arbelaez, M.D. of Baltimore Substance Abuse Systems, and Ryan J. Petteway,
More informationRetrospective Drug Use Review for the Use of Psychotropic Medications in Children
Retrospective Drug Use Review for the Use of Psychotropic Medications in Children Recommendations Send providers an annual request for additional clinical data for children receiving any of the following
More informationChapter 4 ~ Central nervous system
Chapter 4 ~ Central Nervous System: General Section 1 of 6 Chapter 4 ~ Central nervous system 4.1 Hypnotics and anxiolytics 4.1.1 Hypnotics CHLORAL HYDRATE CLOMETHIAZOLE NITRAZEPAM TEMAZEPAM TRICLOFOS
More informationSupplementary Online Content
Supplementary Online Content Lin DH, Jones CM, Compton WM, et al. Prescription drug coverage for treatment of low back pain among US Medicaid, Medicare Advantage, and commercial insurers. JAMA Netw Open.
More informationHYSINGLA ER (hydrocodone bitartrate) Prior authorization is not required if prescribed by an oncologist.
Pre - PA Allowance None Prior authorization is not required if prescribed by an oncologist. Prior-Approval Requirements Age 18 years of age or older Diagnosis Patient must have the following: 1. Pain,
More informationPre - PA Allowance. Prior-Approval Requirements LEVORPHANOL TARTRATE. None
Pre - PA Allowance None Prior-Approval Requirements Prior authorization is not required if prescribed by an oncologist and/or the member has paid pharmacy claims for an oncology medication(s) in the past
More informationMay Revised Urine Drug Screen Test Menu Effective mid-june Lauren Anthony, MD, MT(ASCP) SBB Medical Director, Allina Health Laboratory
May 2014 Lauren Anthony, MD, MT(ASCP) SBB Medical Director, Allina Health Laboratory Revised Urine Drug Test Menu Effective mid-june 2014 To better address the complexities of drug screening for different
More informationMORPHINE IR DRUG CLASS Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone)
Pre - PA Allowance Tablets & Suppositories Morphine sulfate tablets Morphine sulfate suppositories Oxymorphone tablets Hydromorphone tablets Hydromorphone suppositories 360 tablets per 90 days OR 360 suppositories
More informationALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY
ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100
More information3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years
Drug Adherence Assessment Report CleanAssure TM (DRIED BLOOD SPOT): Detection Range see NOTES. Prescribed Medications: HYDROMORPHONE (DILAUDID, EXALGO), CYCLOBENZAPRINE (FLEXERIL), METHADONE (METHADOSE),
More informationPharmacotherapy of Pain SUPHAT SUBONGKOT, PHARM.D. BCOP, BCOP CLINICAL PHARMACY DIVISION KHON KAEN UNIVERSITY, THAILAND
Pharmacotherapy of Pain SUPHAT SUBONGKOT, PHARM.D. BCOP, BCOP CLINICAL PHARMACY DIVISION KHON KAEN UNIVERSITY, THAILAND Therapeutic Strategies for Pain and Disability Pharmacotherapy Rehabilitative approaches
More informationNorthSTAR. Pharmacy Manual
NorthSTAR Pharmacy Manual Revised October, 2008 Table of I. Introduction II. III. IV. Antidepressants New Generation Antipsychotic Medications Mood Stabilizers V. ADHD Medications VI. Anxiolytics and Sedative-Hypnotics
More informationPotentially Inappropriate Medication Use in Older Adults 2015 Latest Research
Home Resources Potentially Inappropriate Medication Use in Older Adults 2015 Resources Potentially Inappropriate Medication Use in Older Adults 2015 Latest Research Drugs and Categories of Drugs What these
More information3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D Director: David J.
Drug Adherence Assessment Report Prescribed Medications: NO MEDICATION LIST PROVIDED CONSISTENT RESULTS - REPORTED MEDICATION DETECTED (PARENT DRUG AND/OR METABOLITE) REPORTED PRESCRIPTION FLAG ANTICIPATED
More informationALZHEIMER'S DRUGS. Details. Step 2: Exelon Patch 13.3 mg/24 hour transdermal Exelon Patch 4.6 mg/24 hr transdermal
ALZHEIMER'S DRUGS Products Affected Step 1: donepezil 10 mg disintegrating tablet donepezil 10 mg tablet donepezil 23 mg tablet donepezil 5 mg disintegrating tablet donepezil 5 mg tablet galantamine 12
More informationU T I L I Z A T I O N E D I T S
I N D I A N A H E A L T H C O V E R A G E P R O G R A M S U T I L I Z A T I O N E D I T S A P R I L 1 9, 2 0 1 2 s for s Refer to Provider Bulletin BT200709 for additional information regarding the Mental
More informationEmbeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.39 Subject: Embeda Page: 1 of 8 Last Review Date: September 15, 2017 Embeda Description Embeda (morphine
More informationDrug Adherence Assessment Report
Prescribed Medications: Drug Adherence Assessment Report FENTANYL, OXYCODONE CONSISTENT RESULTS - REPORTED MEDICATION DETECTED (PARENT DRUG AND/OR METABOLITE) REPORTED ANTICIPATED TEST PRESCRIPTION (S)
More informationLevorphanol. Levorphanol Tartrate. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.59 Subject: Levorphanol Page: 1 of 8 Last Review Date: March 16, 2018 Levorphanol Description Levorphanol
More informationin this web service Cambridge University Press
Prescriber's Guide in this web service in this web service Essential Pain Pharmacology The Prescriber's Guide Howard S. Smith Professor of Anesthesiology, Internal Medicine, Physical Medicine and Rehabilitation,
More information3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years
Drug Adherence Assessment Report CleanAssure TM (DRIED BLOOD SPOT): Detection Range see NOTES. Prescribed Medications: NO MEDICATION LIST PROVIDED CONSISTENT RESULTS - MEDICATION DETECTED (PARENT DRUG
More informationMedications and Children Disorders
Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for
More informationeappendix A. Opioids and Nonsteroidal Anti-Inflammatory Drugs
eappendix A. Opioids and Nonsteroidal Anti-Inflammatory Drugs Nonsteroidal Anti-Inflammatory Drugs Nonselective nonsteroidal anti-inflammatory drugs Diclofenac, etodolac, flurbiprofen, ketorolac, ibuprofen,
More informationDuragesic Patch (fentanyl patch) Prior authorization is not required if prescribed by an oncologist
Pre - PA Allowance Quantity 30 patches every 90 days Prior-Approval Requirements Prior authorization is not required if prescribed by an oncologist Age 2 years of age or older Diagnosis Patient must have
More informationHysingla ER. Hysingla ER (hydrocodone bitartrate) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.38 Subject: Hysingla ER Page: 1 of 9 Last Review Date: September 15, 2017 Hysingla ER Description
More informationLevorphanol. Levorphanol Tartrate. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.59 Subject: Levorphanol Page: 1 of 8 Last Review Date: March 17, 2017 Levorphanol Description Levorphanol
More informationCHAPTER 4 PAIN AND ITS MANAGEMENT
CHAPTER 4 PAIN AND ITS MANAGEMENT Pain Definition: An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. Types of Pain
More informationCommittee Approval Date: May 9, 2014 Next Review Date: May 2015
Medication Policy Manual Topic: Branded Antidepressant Medications: - desvenlafaxine-containing medications (Khedezla, Pristiq ) - duloxetine (Cymbalta ) - levomilnacipran (Fetzima ) - milnacipran (Savella
More informationAppendix: Psychotropic Medication Reference Tables
Appendix: Psychotropic Medication Reference Tables How to Use these Tables These reference tables are designed to provide clinic staff with specific medication related criteria for the Polypharmacy, Cardiometabolic
More informationPalliative Care Drug Plan (Plan P) Formulary List of drugs PharmaCare covers
Palliative Care Drug Plan (Plan P) Formulary List of drugs PharmaCare covers This formulary is current as of February 11, 2010. Important Notes: Pharmacists must submit a claim on PharmaNet at the time
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
More informationDrugs Found in Medical Examiner Cases
s Found in Medical Examiner Cases 1,1 difluoroethane propellant in aerosols 10-Hydroxycarbazepine 11-Hydroxy Delta-9 THC 6-monoacetylmorphine 7-amino clonazepam acetaminophen acetone alpha-hydroxyalprazolam
More informationDuragesic patch. Duragesic patch (fentanyl patch) Description. Section: Prescription Drugs Effective Date: January 1, 2019
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Duragesic patch Page: 1 of 9 Last Review Date: November 30, 2018 Duragesic patch Description Duragesic patch (fentanyl
More informationXyrem (Sodium Oxybate)
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationNSAID all (Warner-Schmidt) includes all (NSAIDs, Salicytes, and Cox-2 inhibitors)
Table S1. Medications categorized as s all (Warner-Schmidt) includes all (s, Salicytes, and Cox-2 inhibitors) Nonsteroidal anti-inflammatory agents Bromfenac Diclofenac Diclofenac-misoprostol Etodolac
More informationPsychotropic Medication Use in Dementia
Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,
More informationMorphine IR Hydromorphone IR Oxymorphone IR. Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone),
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.33 Subject: Morphine IR Drug Class Page: 1 of 11 Last Review Date: December 8, 2017 Morphine IR Hydromorphone
More informationNucynta IR. Nucynta IR (tapentadol immediate-release) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Nucynta IR Page: 1 of 9 Last Review Date: December 8, 2017 Nucynta IR Description Nucynta IR (tapentadol
More informationHigh-risk medications in older adults drug alternative(s)
Antianxiety Analgesics Antihypertensive High-risk medications in older adults drug alternative(s) Guanabenz Guanfacine Methyldopa Reserpine (greater than 0.1 mg per day) High risk of adverse central nervous
More informationButrans (buprenorphine patch) Description. Section: Prescription Drugs Effective Date: October 1, 2017
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Butrans Page: 1 of 9 Last Review Date: September 15, 2017 Butrans (buprenorphine patch) Description
More information2018 Formulary. (List of Covered Drugs)
Capital Health Plan Advantage Plus (HMO) Capital Health Plan Preferred Advantage (HMO) 2018 Formulary (List of Covered Drugs) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN
More informationProvider Toolkit PFFS/PPO
Provider Toolkit 2014 2015 Y0067_PR_PhysTlkt_0514_IA 05/14/2014 PFFS/PPO TABLE OF CONTENTS Sample Letter from Physician to Patient...4 HEDIS Quick Reference Guide...5 High Risk Medication Formulary Alternative
More informationThe use of prescription psychotropic medication in
DRUGS AND PHARMACOLOGY Effect of Age on the Profile of Psychotropic Users: Results from the 2010 National Ambulatory Medical Care Survey Donovan T. Maust, MD,* David W. Oslin, MD, and Steven C. Marcus,
More information1/27/ New Release, Quest Diagnostics Nichols Institute, Valencia
NEW TESTS Please Note: Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated. Test Code Test Name Effective Date
More informationDuragesic patch. Duragesic patch (fentanyl patch) Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.31 Subject: Duragesic patch Page: 1 of 9 Last Review Date: September 15, 2017 Duragesic patch Description Duragesic patch (fentanyl
More informationWELLCARE/ OHANA HEALTH PLAN 2015 STEP THERAPY CRITERIA (No Changes Made Since: 08/2015)
WELLCARE/ OHANA HEALTH PLAN 2015 STEP THERAPY CRITERIA (No Changes Made Since: 08/2015) **To get updated information about the drugs covered by WellCare/ Ohana, please visit our website (https://www.wellcare.com
More informationMedication Policy Manual
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Topic: High-Cost Antidepressant Medications: - amitriptyline (Elavil ) - bupropion hydrobromide (Aplenzin )
More informationDemerol (meperidine oral tablet, oral solution), Meperitab (oral tablet)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Meperidine Page: 1 of 7 Last Review Date: September 15, 2017 Meperidine Description Demerol (meperidine
More informationTarginiq ER (oxycodone/naloxone extended-release), Troxyca ER (oxycodone /naltrexone extended-release)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.44 Subject: Oxycodone Naloxone Page: 1 of 9 Last Review Date: December 2, 2016 Oxycodone Naloxone
More informationSouth London and the Maudsley NHS Foundation Trust Medicines Formulary
South London and the Maudsley NHS Foundation Trust Medicines Formulary Medicine Formulations Restrictions Additional Information / Related NICE Technology Appraisal 4.1 Hypnotics and anxiolytics 4.1.1
More informationBelbuca (buprenorphine buccal film) Belbuca (buprenorphine buccal film) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Belbuca Page: 1 of 9 Last Review Date: September 15, 2017 Belbuca (buprenorphine buccal film)
More information2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+)
2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) In some cases, UCare requires you to first try certain drugs to
More informationDuragesic patch. Duragesic patch (fentanyl patch) Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.31 Section: Prescription Drugs Effective Date: April1, 2017 Subject: Duragesic patch Page: 1 of 10 Last Review Date: March
More informationAvailable Strengths Limits. 10 mg tablet -- $ mg tablet -- $ mg tablet -- $ mg tablet -- $72.41 Avoid use in members over
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Fibromyalgia P&T DATE: 5/9/2017 CLASS: Pain Management REVIEW HISTORY 9/15, 5/14, 11/12, 9/12, LOB: Medi-Cal (MONTH/YEAR)
More informationIMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members
IMPORTANT NOTICE Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members These changes apply only to members covered under the DC Healthcare Alliance program Alliance
More information90 dosage units per 90 days OR. Extended-release Formulations Ultram ER 90 dosage units per 90 days OR
Pre - PA Allowance 12 years of age or older Quantity Immediate-release Formulation Ultracet 720 dosage units per 90 days OR Ultram 720 dosage units per 90 days Extended-release Formulations Ultram ER 90
More informationMO Medicaid Foster Care Drugs FY10-FY14
MO Medicaid Foster Care Drugs FY10-FY14 Medicaid (MO HealthNet) Cost of Drugs given to Missouri Foster Care Children by combinations of Age, Gender, Drug Class and Fiscal Year [Raw Data Provided by Missouri
More informationPHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14
More informationused for dealing with anxiety. Both of the drugs are also given to patients for dealing with pain activated by damaged or hypersensitive nerves that i
Aspirin (also classified under NSAIDs or acetylsalicylic acid). Morphine and morphine sustained release (MS-Contin, Avinza, Kadian) Oxymorphone (Opana, Opana ER) Hydrocodone with acetaminophen (Lortab
More informationHorizon Blue Cross Blue Shield of New Jersey. Horizon Medicare Blue (PPO) 2018 Formulary. (List of Covered Drugs)
.., Horizon Blue Cross Blue Shield of New Jersey Horizon Medicare Blue (PPO) 2018 Formulary (List of Covered Drugs) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN
More informationBelbuca (buprenorphine buccal film) Description. Section: Prescription Drugs Effective Date: October 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Belbuca Page: 1 of 9 Last Review Date: September 15, 2016 Belbuca (buprenorphine buccal film)
More informationUse of Psychotropic Medications in Older Adults with Dementia!
Use of Psychotropic Medications in Older Adults with Dementia! Deepa Pattani, PharmD, RPh Owner: PrevInteract Health Deepa.Pattani@PrevInteract.com 972-372-9775 About Me Deepa Pattani, PharmD, RPh with
More information2015 Annual Physician Notice
0 Annual Physician Notice The Office of Inspector General (OIG) recommends clinical laboratories send notices to physicians and other providers who use their services, at least once a year, to inform the
More information2017 Formulary. (List of Covered Drugs)
Capital Health Plan Advantage Plus (HMO) Capital Health Plan Preferred Advantage (HMO) 2017 Formulary (List of Covered Drugs) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN
More informationMethadone. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.41 Subject: Methadone Page: 1 of 11 Last Review Date: September 15, 2017 Methadone Description Dolophine
More informationOXYCODONE IR (oxycodone)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Oxycodone hydrochloride, a pure opioid agonist, is used in the treatment of moderate to severe pain (1-2). The precise mechanism of action is unknown; however,
More informationProposed Changes to Existing Measure for HEDIS : Use of Opioids at High Dosage (UOD)
Proposed Changes to Existing Measure for HEDIS 1 2020: Use of Opioids at High Dosage (UOD) NCQA seeks comments on proposed revisions to the Use of Opioids at High Dosage HEDIS measure. The current measure
More informationMedi-Pak Advantage (PFFS)
Medi-Pak Advantage (PFFS) 2018 Comprehensive Formulary (List of Covered Drugs) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN Formulary 00018143, version 15 This
More informationFormulary. BlueMedicare SM Comprehensive. BlueMedicare Value (PPO) H ,024,025
BlueMedicare SM Comprehensive Formulary BlueMedicare Value (PPO) H5434-023,024,025 This formulary was updated on 12/28/2018. For more recent information or other questions, please contact Florida Blue
More informationMethadone. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.41 Subject: Methadone Page: 1 of 13 Last Review Date: March 16, 2018 Methadone Description Dolophine
More informationRichard Heidenfelder M.D. Child, Adolescent and Adult Psychiatry 447 9th Ave San Diego, CA
*We are not accepting any New Patients who are currently taking any controlled pain medications *We are *Note: not completion accepting of the any following New Patients paperwork who and Initial are Screening
More informationOhana Community Care Services (CCS) Comprehensive Preferred Drug List (List of Covered Drugs)
2015 Ohana Community Care Services (CCS) Comprehensive referred Drug List (List of Covered Drugs) Ohana Health lan 00 lease read: This document contains information about the drugs we cover in this plan.
More informationSafe transfer of prescribing guidance
Safe transfer of prescribing guidance TEWV Prescriber Summary Application required before prescribing Products requiring an application, before prescribing, using the single application form Unlicensed
More informationWorking together to improve health care quality, outcomes, and affordability in Washington State. Opioid Prescribing Metrics
Working together to improve health care quality, outcomes, and affordability in Washington State. Opioid Prescribing Metrics July 2017 Table of Contents Background... 1 How to Use the Metrics... 1 Future
More informationLCMS-8050 Drugs of Abuse: 113 Analytes with Polarity Switching
Liquid Chromatography Mass Spectrometry SSI-LCMS-8 LCMS-8 Drugs of Abuse: Analytes with Polarity Switching LCMS-8 Summary Seventy six analytes and their internal standards are described below. Multiple
More informationAlaska Medicaid 90 Day** Generic Prescription Medication List
1 ACYCLOVIR 200 MG CAPSULE BUPROPION HCL 150 MG TAB ER 24H ACYCLOVIR 200 MG/5ML BUPROPION HCL 150 MG TABLET ER ACYCLOVIR 400 MG TABLET BUPROPION HCL 150 MG TABLET ER ACYCLOVIR 800 MG TABLET BUPROPION HCL
More informationPSYCHIATRY INTAKE FORM
Please complete all information on this form. PSYCHIATRY INTAKE FORM Name Date Date of Birth Primary Care Physician Current Therapist/Counselor What are the problem(s) for which you are seeking help? 1.
More informationCOLCRYS-PST. Products Affected Step 1: Mitigare 0.6 mg capsule. Details. Step 2: Colcrys 0.6 mg tablet
COLCRYS-PST Mitigare 0.6 mg capsule Colcrys 0.6 mg tablet Criteria If the patient has tried one Step 1 product, authorization for a Step 2 product may be given. Exceptions can be made for a step 2 drug
More informationOxycodone. Oxycodone IR, Oxycodone ER, OxyContin, Xtampza ER. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Oxycodone Page: 1 of 11 Last Review Date: March 17, 2017 Oxycodone Description Oxycodone IR, Oxycodone
More informationOxycodone. Oxycodone IR, Oxycodone ER, OxyContin, Xtampza ER. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Oxycodone Page: 1 of 10 Last Review Date: September 15, 2016 Oxycodone Description Oxycodone IR,
More informationPAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose
NON-OPIOID SHORT-ACTING LONG-ACTING **** O PAIN TREATMENT TABLES Analgesics NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose Tramadol 50 mg Ultram Every 4 hours 1-2 tabs,
More informationCENPATICO INTEGRATED CARE BEHAVIORAL HEALTH DRUG LIST BY DRUG NAME. Use Brand Only
ACAMPROSATE TABLET DELAYED RELEASE ALPHA-TOCOPHEROL CAPSULES ALPRAZOLAM CONCENTRATE 1 MG/ML ALPRAZOLAM ODT TABLET 0.25MG, 0.5MG, 1MG ALPRAZOLAM ODT TABLET 2MG ALPRAZOLAM SR TABLET 24-HOUR ALPRAZOLAM TABLET
More informationXartemis XR (oxycodone / acetaminophen extended release)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Xartemis XR is a combination of oxycodone and acetaminophen in a dosage formulation to deliver both immediate pain relief, in less than an hour, and extended-release
More informationMorphine Sulfate Hydromorphone Oxymorphone
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.33 Subject: Morphine Drug Class Page: 1 of 12 Last Review Date: September 15, 2017 Morphine Sulfate
More informationAmbetter 90-Day-Supply Maintenance Drug List
Ambetter 90-Day-Supply Maintenance Drug List What is the Ambetter 90-Day-Supply Maintenance Drug List? Ambetter 90-Day-Supply Maintenance Drug List is a list of maintenance medications that are available
More informationFormulary (Drug List)
Formulary (Drug List) PacificSource Community Solutions This list was updated on /5/07 Please Read: This document contains information about the drugs we cover on this plan. For a complete, up-to-date
More informationCNS DEPRESSANT OVERDOSE
Signs and symptoms of CNS depressant overdose include: altered mental status, respiratory depression, hypotension, bradycardia, pulmonary edema, coma, and constricted pupils (opioids only). The following
More informationCHAPTER 4 PAIN AND ITS MANAGEMENT
CHAPTER 4 PAIN AND ITS MANAGEMENT Pain Definition: An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. Types of Pain
More informationScreening - inclusion criteria
A Date of data collection: B Time of data collection: C Ward where data is collected: 2 0 1 Y M M D D H H M M D Research assistant Code: Patient code (local): Room number: Screening - inclusion criteria
More informationCOLCRYS-PST. Products Affected Step 1: Mitigare 0.6 mg capsule. Details. Step 2: Colcrys 0.6 mg tablet
COLCRYS-PST Mitigare 0.6 mg capsule Colcrys 0.6 mg tablet Criteria If the patient has tried one Step 1 product, authorization for a Step 2 product may be given. Exceptions can be made for a step 2 drug
More informationSupplementary figures and tables. Figure A: Study schematic
Supplementary figures and tables Figure A: Study schematic Figure B: Percent of patients with a normal (green), borderline (beige), abnormal (brown), or high (red) electrocardiogram 14-90 days after prescription
More informationHappy Daisy Ltd. New Client intake Form. What are the issues for which you are seeking care?
Happy Daisy Ltd. New Client intake Form Name Date Preferred name Pronouns Referred by Date of birth Age Race What are the issues for which you are seeking care? 1. 2. 3. Please check of any of the symptoms
More informationSupplementary Online Content
Supplementary Online Content Renoux C, Vahey S, Dell Aniello S, Boivin J-F. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol. Published
More informationAppendix. TABLE E-1 Study Variables and Associated ICD-9-CM, HCPCS, and CPT Codes. Codes. (1) Fracture locations
Page 1 Appendix TABLE E-1 Study Variables and Associated ICD-9-CM, HCPCS, and CPT Codes (1) Fracture locations Vertebral fracture Codes ICD-9-CM Diagnosis codes: 733.13, 805.xx, 806.xx ICD-9-CM Procedure
More informationAETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization
AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization Policy applies to all formulary and non-formulary schedules II V opioid narcotics, including tramadol and codeine, as
More information